The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...
Drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) have shown remarkable efficacy in helping individuals achieve significant weight loss, and combined with behavioral counseling ...
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
Health 2024-12-24T21:08:59Z The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result. The weight loss medication tirzepatide (Mounjaro ...
The MHRA warns against buying weight-loss medicines illegally, emphasizing health risks and the need for prescriptions from ...
Cheaper versions of the drug, known as compounded tirzepatide, might be restricted in 2025. Patients could face higher costs and tougher access, and telehealth is racing to adapt. The FDA has ...